Cargando…
Tumor necrosis factor α knockout impaired tumorigenesis in chronic myeloid leukemia cells partly by metabolism modification and miRNA regulation
PURPOSE: Half of the chronic myeloid leukemia (CML) patients with sustained deep molecular response suffer from relapse after discontinuation mainly because tyrosine kinase inhibitors (TKIs) cannot eradicate leukemia stem cells (LSCs). In addition, tumor necrosis factor α (TNF-α) is highly detected...
Autores principales: | Shen, Na, Liu, Songya, Cui, Jieke, Li, Qing, You, Yong, Zhong, Zhaodong, Cheng, Fanjun, Guo, An-Yuan, Zou, Ping, Yuan, Guolin, Zhu, Xiaojian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446984/ https://www.ncbi.nlm.nih.gov/pubmed/31015764 http://dx.doi.org/10.2147/OTT.S197535 |
Ejemplares similares
-
ACSL1 promotes imatinib-induced chronic myeloid leukemia cell senescence by regulating SIRT1/p53/p21 pathway
por: Liu, Wen, et al.
Publicado: (2022) -
A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors
por: Li, Qing, et al.
Publicado: (2016) -
Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells
por: Chen, Yilin, et al.
Publicado: (2021) -
Case Report: Multi-Omics Analysis and CAR-T Treatment of a Chronic Myeloid Leukemia Blast Crisis Case 5 Years After the Discontinuation of TKI
por: Miao, Ya-Ru, et al.
Publicado: (2021) -
miRNAs in acute myeloid leukemia
por: Liao, Qiong, et al.
Publicado: (2016)